Category «Uncategorized»

ELAGOLIX

ELAGOLIX Molecular FormulaC32H30F5N3O5 Average mass631.590 Da NBI56418, ABT 620 UNII:5B2546MB5Z 4-({(1R)-2-[5-(2-Fluoro-3-methoxyphenyl)-3-[2-fluoro-6-(trifluoromethyl)benzyl]-4-methyl-2,6-dioxo-3,6-dihydro-1(2H)-pyrimidinyl]-1-phenylethyl}amino)butanoic acid 834153-87-6 FREE ACID SODIUM SALT 832720-36-2 Acide 4-({(1R)-2-[5-(2-fluoro-3-méthoxyphényl)-3-[2-fluoro-6-(trifluorométhyl)benzyl]-4-méthyl-2,6-dioxo-3,6-dihydro-1(2H)-pyrimidinyl]-1-phényléthyl}amino)butanoïque Butanoic acid, 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]- GNRH antagonist, Endometriosis Endometriosis PREREGISTERED Phase III Uterine leiomyoma WO2001055119A2, Inventors Yun-Fei Zhu, Chen Chen, Fabio C. Tucci, Zhiqiang Guo, Timothy D. Gross, Martin Rowbottom, R. Scott Struthers, Applicant Neurocrine Biosciences, Inc. WO 2005007165 PDT PATENT Inventors Zhiqiang Guo, Yongsheng Chen, Dongpei Wu, Chen …

Empesertib , BAY 1161909

Empesertib , BAY 1161909, Mps1-IN-5, (-)-BAY-1161909 CAS 1443763-60-7 Chemical Formula: C29H26FN5O4S Molecular Weight: 559.6164 [a]D20 : -78.9° (in DMSO). WO 2014198647 UNII-02Y3Z2756M (αR)-4-Fluoro-N-[4-[2-[[2-methoxy-4-(methylsulfonyl)phenyl]amino][1,2,4]triazolo[1,5-a]pyridin-6-yl]phenyl]-α-methylbenzeneacetamide (R)-2-(4-fluorophenyl)-N-(4-(2-((2-methoxy-4-(methylsulfonyl)phenyl)amino)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl)propanamide (2R)-2-(4-Fluorophenyl)-N-(4-(2-((4-(methanesulfonyl)-2-methoxyphenyl)amino)(1,2,4)triazolo(1,5-a)pyridin-6-yl)phenyl)propanamide Benzeneacetamide, 4-fluoro-N-(4-(2-((2-methoxy-4-(methylsulfonyl)phenyl)amino)(1,2,4)triazolo(1,5-a)pyridin-6-yl)phenyl)-alpha-methyl-, (alphaR)- PHASE 1, BAYER, CANCER PRODUCT PATENT, WO2013087579, https://www.google.com/patents/WO2013087579A1 SYNTHESIS, WO 2014198647 Analytical UPLC-MS was performed as follows: Method A: System: UPLC Acquity (Waters) with PDA Detector und Waters ZQ mass spectrometer; Column: Acquity …

Psilocybin, псилоцибин , بسيلوسيبين , 赛洛西宾 ,

Psilocybin Molecular FormulaC12H17N2O4P Average mass284.248 Da 4-22-00-05665 (Beilstein Handbook Reference) [Beilstein] 520-52-5 [RN] 1H-Indol-4-ol, 3-[2-(dimethylamino)ethyl]-, dihydrogen phosphate (ester) 208-294-4 [EINECS] 3-[2-(Dimethylamino)ethyl]-1H-indol-4-ol Dihydrogen Phosphate Ester псилоцибин [Russian] [INN] بسيلوسيبين [Arabic] [INN] 赛洛西宾 [Chinese] [INN] NM 3150000 O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine P-7825 PDSP1_001391 UNII-2RV7212BP0 MP 220-228 deg C, O’Neil, M.J. (ed.). The Merck Index – An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition, Whitehouse Station, …

Hypericin

Hypericin Hypericin is a naphthodianthrone, an anthraquinone derivative which, together with hyperforin, is one of the principal active constituents of Hypericum (Saint John’s wort).[2][3] Hypericin is believed to act as an antibiotic, antiviral[2] and non-specific kinaseinhibitor. Hypericin may inhibit the action of the enzyme dopamine β-hydroxylase, leading to increased dopamine levels, although thus possibly decreasing norepinephrine and epinephrine. It was initially believed that the anti-depressant pharmacological activity of hypericin was due …

Normal Operating Range (NOR) and Proven Acceptable Range (PAR)

In June of this year, the EMA issued a revision of their earlier Q&A document focused on NORs, PARs, and DSp.(2) First issued in draft form in 2015, this has been revised based on feedback and consultation with industry. The document focuses on five questions, which are summarized below along with a reflection on the answer …

Upadacitinib, ABT-494, упадацитиниб , أوباداسيتينيب , 乌帕替尼 ,

ABT 494 (-)-(3S,4R) cis form CAS 1310726-60-3 FREE FORM MF C17H19F3N6O MW 380.36757 g/mol Tartrate form C17 H19 F3 N6 O . C4 H6 O6 . 4 H2 O ………….CAS 1607431-21-9 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, (3S,4R)-, (2R,3R)-2,3-dihydroxybutanedioate, hydrate (1:1:4) FREE FORM (3s,,4R)-3-ethyl-4-(3H-imidazo[l,2-fl]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine- l-carboxamide. (35,,4R)-3-ethyl-4-(3H- imidazo[l,2-fl]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine- l-carboxamide, (cis,)-3-ethyl-4-(3H-imidazo[l,2-fl]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-l-carboxamide 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, (3S,4R)- rel-(-)-(3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide A Jak1 inhibitor potentially for the treatment …

LL 3858, SUDOTERB From LUPIN For TB

LL 3858, SUDOTERB UNII-SK2537665A; CAS 676266-31-2; N-[2-methyl-5-phenyl-3-[[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]pyrrol-1-yl]pyridine-4-carboxamide; N-[2-Methyl-5-phenyl-3-[[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]methyl]-1H-pyrrol-1-yl]-4-pyridinecarboxamide Sudoterb(TM) Molecular Formula: C29H28F3N5O Molecular Weight: 519.572 g/mol Originator Lupin Class Antituberculars; Isonicotinic acids; Pyrroles Mechanism of Action Undefined mechanism Orphan Drug Status No New Molecular Entity Yes Highest Development Phases No development reported Tuberculosis Most Recent Events 23 Jul 2015 No recent reports on development identified – Phase-II for Tuberculosis in India (unspecified …

Continuous-Flow Preparation of γ-Butyrolactone Scaffolds, 2-(5,5-dimethyl-2-oxotetrahydrofuran-3- yl)acetic acid

(5,5-dimethyl-2-oxotetrahydrofuran-3-yl)acetic acid 2-(5,5-Dimethyl-2-oxotetrahydrofuran-3-yl)acetic acid 2-carboxymethyl-4-methyl-4-pentanolide, Cas 412298-86-3 2-(5,5-Dimethyl-2-oxotetrahydrofuran-3-yl)acetic acid (4a). 1H NMR (DMSO-d6, 400 MHz): δ = 3.20 – 3.10 (m, 1H), 2.62 (dd, J = 17.1, 4.4 Hz, 1H), 2.54 – 2.45 (m, 1H), 2.31 – 2.21 (m, 1H), 1.84 (t, J = 12.0 Hz, 1H), 1.39 (s, 3H), 1.33 (s, 3H) …

Palladium-catalyzed direct C-H ethoxycarbonylation of 2-aryl-1,2,3-triazoles and efficient synthesis of suvorexant

Palladium-catalyzed direct C-H ethoxycarbonylation of 2-aryl-1,2,3-triazoles and efficient synthesis of suvorexant Org. Chem. Front., 2018, Advance Article DOI: 10.1039/C7QO00945C, Research Article Rui Sang, Yang Zheng, Hailong Zhang, Xiaohua Wu, Qiantao Wang, Li Hai, Yong Wu Palladium-catalyzed direct ethoxycarbonylation with diethyl azodicarboxylate was developed and its reaction mechanism was explored by using DFT calculations. Palladium-catalyzed …

2,4-dimorpholinocyclopent-2-enone

1465003-25-1 cas 2,4-dimorpholinocyclopent-2-enone (1b): 1H NMR (300 MHz, CDCl3) 6.24 (d, J = 2.9 Hz, 1H, COC=CH), 3.78 (t, J = 4.7 Hz, 4H, morpholine), 3.73 (t, J = 4.7 Hz, 4H, morpholine), 3.73-3.72 (m, 1H, COCH2CHN), 3.15-3.14 (m, 4H, morpholine), 2.54-2.52 (m, 4H, morpholine), 2.49-2.48 (m, 1H, COCH2), 2.46-2.45 (m, 1H, COCH2); …